|
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 139-144.
Prepublished online as a Blood First Edition Paper on September 7, 2006; DOI 10.1182/blood-2006-04-014654.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
Martin den Heijer1,,
Huub P. J. Willems2,
Henk J. Blom3,
Wim B. J. Gerrits2,
Marco Cattaneo4,
Sabine Eichinger5,
Frits R. Rosendaal6, and
Gerard M. J. Bos7
1 Department of Endocrinology and Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;
2 Department of Hematology, Leyenburg Hospital, The Hague, The Netherlands;
3 Laboratory of Paediatrics and Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;
4 Unit of Hematology and Thrombosis, Ospedale San Paolo, University of Milano, Milano, Italy;
5 Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;
6 Department of Clinical Epidemiology and Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; and
7 Department of Hematology, University Hospital Maastricht, Maastricht, The Netherlands
The Vitamins and Thrombosis (VITRO) study investigated the effect of homocysteine lowering by daily supplementation of B vitamins on the risk reduction of deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients between 20 to 80 years old with a first objectively confirmed proximal DVT or PE in the absence of major risk factors and a homocysteine concentration above the 75th percentile of a reference group were asked to participate (hyperhomocysteinemic group). A similar study was conducted in a random sample of patients with a homocysteine below the 75th percentile of the reference group (normohomocysteinemic group). After informed consent was obtained, patients were randomized to daily multivitamin supplementation (5 mg folic acid, 50 mg pyridoxine, and 0.4 mg cyanocobalamin) or placebo and were followed for 2.5 years. End points were objectively diagnosed recurrent DVT or PE. A total of 701 patients were enrolled (360 in the hyperhomocysteinemic and 341 in the normohomocysteinemic group). The number of recurrent events of venous thrombosis was 43 of 353 in the vitamin group (54/1000 py) and 50 of 348 in the placebo group (64/1000 py). The hazard ratio associated with vitamin treatment was 0.84 (95% CI, 0.56-1.26): 1.14 (95% CI, 0.65-1.98) in the hyperhomocysteinemic group and 0.58 (95% CI, 0.31-1.07) in the normohomocysteinemic group. The results of our study do not show that homocysteine lowering by B vitamin supplementation prevents recurrent venous thrombosis. This trial was registered at www.clinicaltrials.gov as #NCT00314990
[ClinicalTrials.gov]
.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
Vitamins and Thrombosis (VITRO) studyhomocysteine lowering with B vitamins
- Antonis Georg Tsamaloukas
Blood 2007 109: 5520-5521.
[Full Text]
[PDF]
-
Response: Homocysteine lowering and recurrent venous thrombosis: the VITRO trial
- Martin den Heijer, Henk J. Blom, Frits R. Rosendaal, and Gerard M. J. Bos
Blood 2007 109: 5521-5522.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
R. N. Rodionov and S. R. Lentz
The Homocysteine Paradox
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2008;
28(6):
1031 - 1033.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee
Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation
Circ. Res.,
April 25, 2008;
102(8):
933 - 941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ryan-Harshman and W. Aldoori
Vitamin B12 and health
Can Fam Physician,
April 1, 2008;
54(4):
536 - 541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. M. Lijfering, N. J.G.M. Veeger, J.-L. P. Brouwer, and J. van der Meer
The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels
Haematologica,
December 1, 2007;
92(12):
1703 - 1706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Hron, R. Lombardi, S. Eichinger, A. Lecchi, P. A. Kyrle, and M. Cattaneo
Low vitamin B6 levels and the risk of recurrent venous thromboembolism
Haematologica,
September 1, 2007;
92(9):
1250 - 1253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Marcucci, F. Sofi, A. M. Gori, G. F. Gensini, and R. Abbate
Vitamin supplementation in the secondary prevention of venous thromboembolism: about the VITRO study
Blood,
June 15, 2007;
109(12):
5520 - 5520.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Tsamaloukas
Vitamins and Thrombosis (VITRO) study--homocysteine lowering with B vitamins
Blood,
June 15, 2007;
109(12):
5520 - 5521.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Ray, C. Kearon, Q. Yi, P. Sheridan, E. Lonn, and for the Heart Outcomes Prevention Evaluation 2 (HO
Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism: A Randomized Trial
Ann Intern Med,
June 5, 2007;
146(11):
761 - 767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bathum, I. Petersen, L. Christiansen, A. Konieczna, T. I.A. Sorensen, and K. O. Kyvik
Genetic and Environmental Influences on Plasma Homocysteine: Results from a Danish Twin Study
Clin. Chem.,
May 1, 2007;
53(5):
971 - 979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. D. Bezemer, C. J. M. Doggen, H. L. Vos, and F. R. Rosendaal
No Association Between the Common MTHFR 677C->T Polymorphism and Venous Thrombosis: Results From the MEGA Study
Arch Intern Med,
March 12, 2007;
167(5):
497 - 501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Homocysteine-Lowering Therapy After Venous Thromboembolism
Journal Watch (General),
February 6, 2007;
2007(206):
1 - 1.
[Full Text]
|
 |
|

|
 |

|
 |
 
Venous Thrombosis: The Culprit Is Factor VIII, not Homocysteine
Journal Watch Oncology and Hematology,
January 22, 2007;
2007(122):
6 - 6.
[Full Text]
|
 |
|
| |